(Total Views: 629)
Posted On: 12/21/2021 11:18:56 AM
Post# of 145871
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
This guy gets it. I am so glad that Cytodyn brought in Dr Recknor! From YMB:
dante
Would you look at that the FDA helping CYDY. Thats what happens when you have a guy like Dr.Recknor communicating with FDA and they know you have a QUALIFIED and RESPECTED CRO. “That’s In previous trials we had issues with our CRO that we now have overcome, and are very excited that the FDA in their recent communication with CytoDyn have stated, ‘As there are now several completed, ongoing, or planned randomized trials of PRO140 (leronlimab) that include severe or critical hospitalized COVID-19 patients, any integrated or meta-analysis would be strengthened if you prespecified analysis details and submitted these for review before results of ongoing or planned trials are Unblinded.’ Since the beginning of the current pandemic, leronlimab has received about 100 eINDs approved for leronlimab by the FDA for use in critically ill COVID-19 patients in the U.S., as a result of these FDA approved eINDs and strong results from most of them, physicians have published four papers in peer review journals.“
It is my hope cydy goes after AMAFRAUD with max impact cleaning them out down to the computers in their office. Im talking Coming for everything.
Godfight. This is a new cydy. RECKNOR."
dante
Would you look at that the FDA helping CYDY. Thats what happens when you have a guy like Dr.Recknor communicating with FDA and they know you have a QUALIFIED and RESPECTED CRO. “That’s In previous trials we had issues with our CRO that we now have overcome, and are very excited that the FDA in their recent communication with CytoDyn have stated, ‘As there are now several completed, ongoing, or planned randomized trials of PRO140 (leronlimab) that include severe or critical hospitalized COVID-19 patients, any integrated or meta-analysis would be strengthened if you prespecified analysis details and submitted these for review before results of ongoing or planned trials are Unblinded.’ Since the beginning of the current pandemic, leronlimab has received about 100 eINDs approved for leronlimab by the FDA for use in critically ill COVID-19 patients in the U.S., as a result of these FDA approved eINDs and strong results from most of them, physicians have published four papers in peer review journals.“
It is my hope cydy goes after AMAFRAUD with max impact cleaning them out down to the computers in their office. Im talking Coming for everything.
Godfight. This is a new cydy. RECKNOR."
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)